Genmab GMAB
Nasdaq · Pharmaceutical Preparations$50.60−1.46%Nov 20 close · Databento
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2024, as filed with the SEC · 66-metric EOD snapshot via DatabentoRevenuekr 21.5B +30.7%
True FCF (ex-SBC)kr 7.6B +8.1%
Rule of 4065.9%
ROIC19.7%
FCF Margin35.2%
EPS, dilutedkr 121.36 +83.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh—
EPS (diluted)kr 121.36
Compounder & Returns
Rule of 4065.9%
ROIC19.7%
Cash ROIC (CROIC)28.3%
GP / Assets—
ROE21.4%
ROA17.1%
Gross Margin—
Oper. Margin31.1%
Net Margin36.4%
FCF Margin35.2%
True FCF Margin35.2%
Quality & Dilution
Cash Conversion97%
Accrual Ratio+0.2%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate128%
Sales Growth Y/Y+30.7%
Sales 3Y CAGR+36.8%
EPS Growth Y/Y+83.8%
FCF Growth Y/Y+8.1%
FCF 3Y CAGR+56.6%
Share Change Y/Y—
Balance Sheet & Scale
Revenue (FY)kr 21.5B
Gross Profit (FY)—
Oper. Income (FY)kr 6.7B
GAAP Net Incomekr 7.8B
True FCF (ex-SBC)kr 7.6B
Cash & Equivkr 9.9B
Total Debt—
Net Cash (Debt)kr 9.9B
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio5.25
Price & Technicals (EOD)
Perf Week−1.50%
Perf Month+26.50%
Perf Quarter+53.24%
Perf Half Y+88.31%
Perf YTD+83.87%
SMA 20 Dist−4.11%$52.77
SMA 50 Dist+17.72%$42.98
SMA 100 Dist+36.97%$36.94
Window High−11.68%$57.29
Window Low+112.16%$23.85
RSI (14) · Vol55.297%v
Income Distribution & Cash Flow ConversionHow every dollar of GMAB revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Where Every kr 100 of Revenue Goes (FY2024)
Cost of Revenue (COGS)kr 985.0M (kr 4.6 / kr 100)
R&D Reinvestmentkr 9.7B (kr 45.3 / kr 100)
SG&A & Other OpExkr 4.1B (kr 19.0 / kr 100)
Tax & Non-Operatingkr 0 (kr 0.0 / kr 100)
Net Profit Keptkr 7.8B (kr 31.1 / kr 100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2024)
GAAP Net Incomekr 7.8B (36.4% margin)
Operating Cash Flow (OCF)kr 7.8B(36.1% of rev)
Less: Capital Expenditures−kr 187.0M(0.9% of rev)
Standard Free Cash Flow (FCF)kr 7.6B(35.2% margin)
Less: Stock-Based Comp (SBC)—
True FCF (Owner Cash ex-SBC)kr 7.6B(35.2% of rev)
Revenue by fiscal year
Operating leverage — margins
GrossOperatingNet
| Line Item (DKK) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | kr 10.1B | kr 8.4B | kr 14.5B | kr 16.5B | kr 21.5B | +30.7% | +20.8% | |
| Cost of Revenue (COGS) | — | — | — | kr 226.0M | kr 985.0M | +335.8% | +335.8% | |
| Research & Development (R&D) | kr 3.1B | kr 4.2B | kr 5.6B | kr 7.6B | kr 9.7B | +27.8% | +32.8% | |
| Selling, General & Admin (SG&A) | kr 661.0M | kr 1.3B | kr 2.7B | kr 3.3B | kr 3.8B | +15.0% | +54.7% | |
| Operating Income (EBIT) | kr 6.3B | kr 3.0B | kr 6.3B | kr 5.3B | kr 6.7B | +26.0% | +1.5% | |
| Interest Expense | kr 1.6B | kr 702.0M | kr 2.5B | kr 1.6B | kr 2.0B | +21.7% | +6.1% | |
| Income Tax Expense | kr 1.1B | kr 961.0M | kr 1.5B | kr 1.3B | kr 1.3B | +2.7% | +3.6% | |
| GAAP Net Income | kr 4.8B | kr 3.0B | kr 5.5B | kr 4.4B | kr 7.8B | +80.2% | +13.3% | |
| Diluted EPS | kr 72.21 | kr 44.77 | kr 82.59 | kr 66.02 | kr 121.36 | +83.8% | +13.9% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | kr 7.3B | kr 9.0B | kr 9.9B | kr 14.9B | kr 9.9B | −33.7% | +7.9% | |
| Inventory | kr 62.0M | kr 62.0M | kr 62.0M | kr 57.0M | kr 62.0M | +8.8% | +0.0% | |
| Total Current Assets | kr 18.8B | kr 22.6B | kr 28.2B | kr 33.1B | kr 27.9B | −15.9% | +10.3% | |
| Total Assets | kr 21.1B | kr 24.5B | kr 30.1B | kr 35.3B | kr 45.8B | +29.8% | +21.3% | |
| Total Current Liabilities | kr 1.3B | kr 1.6B | kr 1.8B | kr 2.5B | kr 5.3B | +113.7% | +43.5% | |
| Total Liabilities | kr 2.0B | kr 2.4B | kr 2.8B | kr 3.7B | kr 9.1B | +147.7% | +45.7% | |
| Stockholders' Equity | kr 19.1B | kr 22.1B | kr 27.3B | kr 31.6B | kr 36.7B | +16.1% | +17.7% | |
| Net Cash / (Net Debt) | kr 7.3B | kr 9.0B | kr 9.9B | kr 14.9B | kr 9.9B | −33.7% | +7.9% | |
| Invested Capital | kr 11.9B | kr 13.2B | kr 17.4B | kr 16.7B | kr 26.8B | +60.3% | +22.6% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | kr 6.4B | kr 2.2B | kr 3.9B | kr 7.4B | kr 7.8B | +5.3% | +4.8% | |
| Depreciation & Amortization (D&A) | kr 79.0M | kr 110.0M | — | — | kr 110.0M | — | +8.6% | |
| Capital Expenditures (CapEx) | kr 307.0M | kr 252.0M | kr 317.0M | kr 366.0M | kr 187.0M | −48.9% | −11.7% | |
| Free Cash Flow (FCF) | kr 6.1B | kr 2.0B | kr 3.6B | kr 7.0B | kr 7.6B | +8.1% | +5.5% | |
| True FCF (ex-SBC Owner Cash) | kr 6.1B | kr 2.0B | kr 3.6B | kr 7.0B | kr 7.6B | +8.1% | +5.5% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what GMAB did at the next close after each storyJul 8
Genmab reports positive Epkinly trial results in DLBCL, expanding addressable market
—Yahoo Finance · 11:04 AM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.